Literature DB >> 10532648

Plasma lactoferrin levels are decreased in end-stage AIDS patients.

B W van der Strate1, M C Harmsen, T H The, H G Sprenger, H de Vries, M C Eikelboom, M E Kuipers, D K Meijer, P J Swart.   

Abstract

The antimicrobial protein lactoferrin (Lf) is present in plasma and in mucosal secretions. Using ELISA we analysed plasma and saliva of HIV-infected patients, patients with AIDS, and healthy controls for the presence of secreted Lf. The plasma Lf levels of AIDS patients (classification C3) were significantly lower (p < 0.001) as compared to asymptomatic and symptomatic HIV infected patients, or controls. In addition, plasma Lf levels closely correlated with neutrophilic granulocyte counts in the HIV-infected patients. Thus, basal plasma Lf levels are likely the result of Lf release by neutrophilic granulocytes. The Candida titres present in the oral cavity were determined in a part of the HIV-infected patient group. As it appeared, the presence of this opportunistic pathogen always coincided with low levels of salivary Lf levels. We conclude that Lf, as part of the nonspecific immune system, might play an important role in the first line of defense against opportunistic microbial infections in AIDS patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10532648     DOI: 10.1089/vim.1999.12.197

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  7 in total

1.  The antiviral protein human lactoferrin is distributed in the body to cytomegalovirus (CMV) infection-prone cells and tissues.

Authors:  Leonie Beljaars; Hester I Bakker; Barry W A van der Strate; Catharina Smit; Adrian M Duijvestijn; Dirk K F Meijer; Grietje Molema
Journal:  Pharm Res       Date:  2002-01       Impact factor: 4.200

2.  Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical Candida isolates.

Authors:  M E Kuipers; H G de Vries; M C Eikelboom; D K Meijer; P J Swart
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

3.  Antifungal effects of lysozyme and lactoferrin against genetically similar, sequential Candida albicans isolates from a human immunodeficiency virus-infected southern Chinese cohort.

Authors:  Y H Samaranayake; L P Samaranayake; E H Pow; V T Beena; K W Yeung
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

4.  Viral load in breast milk correlates with transmission of human cytomegalovirus to preterm neonates, but lactoferrin concentrations do not.

Authors:  B W van der Strate; M C Harmsen; P Schäfer; P J Swart; T H The; G Jahn; C P Speer; D K Meijer; K Hamprecht
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

5.  Action of deferoxamine against Pneumocystis carinii.

Authors:  A B Clarkson; D Turkel-Parrella; J H Williams; L C Chen; T Gordon; S Merali
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

6.  Inhibition of HBV infection by bovine lactoferrin and iron-, zinc-saturated lactoferrin.

Authors:  Songtao Li; Haibo Zhou; Guirong Huang; Ning Liu
Journal:  Med Microbiol Immunol       Date:  2008-09-23       Impact factor: 3.402

7.  Inhibition of intestinal polyp growth by oral ingestion of bovine lactoferrin and immune cells in the large intestine.

Authors:  Masaaki Iigo; David B Alexander; Jiegou Xu; Mitsuru Futakuchi; Masumi Suzui; Takahiro Kozu; Takayuki Akasu; Daizo Saito; Tadao Kakizoe; Koji Yamauchi; Fumiaki Abe; Mitsunori Takase; Kazunori Sekine; Hiroyuki Tsuda
Journal:  Biometals       Date:  2014-05-28       Impact factor: 2.949

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.